Compare CMTL & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMTL | BTAI |
|---|---|---|
| Founded | 1967 | 2017 |
| Country | United States | United States |
| Employees | 1385 | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.1M | 35.6M |
| IPO Year | 2024 | 2018 |
| Metric | CMTL | BTAI |
|---|---|---|
| Price | $4.67 | $1.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $6.00 | ★ $25.33 |
| AVG Volume (30 Days) | 221.6K | ★ 1.1M |
| Earning Date | 03-16-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $499,528,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.97 | $261.81 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.19 | $1.17 |
| 52 Week High | $6.21 | $8.08 |
| Indicator | CMTL | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 37.32 | 42.83 |
| Support Level | $2.74 | $1.33 |
| Resistance Level | $6.15 | $2.20 |
| Average True Range (ATR) | 0.37 | 0.15 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 3.57 | 11.84 |
Comtech Telecommunications Corp is a provider of communications technology and solutions. It operates in two reportable business segments: Satellite and Space Communications and Allerium. The company's Satellite and Space Communications segment, which generates maximum revenue, is organized into four technology areas: satellite modem and amplifier technologies, troposcatter technologies, cybersecurity training, and space components. This segment designs and manufactures modems, amplifiers, traveling wave tube amplifiers, frequency converters, and offers other associated software and services. The Allerium segment provides next-generation 911 (NG-911) infrastructure and solutions for state and local governments and carriers. Geographically, the company derives its key revenue from the USA.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.